公开(公告)号：US09822353B2

公开(公告)日：2017-11-21

申请号：US14360573

申请日：2012-12-06

Applicant: aTyr Pharma, Inc.

Inventor： Ying Ji Buechler ,  Chi-Fang Wu ,  Jeffrey Greve ,  John D. Mendlein

IPC: C12N9/96 ,  A61K38/43 ,  C12N9/00 ,  A61K47/48 ,  A61K38/00 ,  A61K38/53

CPC classification number: C12N9/93 ,  A61K38/00 ,  A61K38/53 ,  A61K47/60 ,  C12N9/96 ,  C12Y601/01012 ,  C12Y601/01023 ,  Y02A50/411

Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.

公开(公告)号：US20150159148A1

公开(公告)日：2015-06-11

申请号：US14360573

申请日：2012-12-06

Applicant: aTyr Pharma, Inc.

Inventor： Ying Ji Buechler ,  Chi-Fang Wu ,  Jeffrey Greve ,  John D. Mendlein

IPC: C12N9/00 ,  C12N9/96

CPC classification number: C12N9/93 ,  A61K38/00 ,  A61K38/53 ,  A61K47/60 ,  C12N9/96 ,  C12Y601/01012 ,  C12Y601/01023 ,  Y02A50/411

Abstract: The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.

Abstract translation: 本发明提供聚乙二醇化天冬氨酰-tRNA合成酶（DRS）多肽，包含其的组合物，以及使用这些多肽和组合物治疗或诊断各种病症的方法。 与非聚乙二醇化DRS多肽相比，本发明的聚乙二醇化DRS多肽具有改善的控制释放性质，稳定性，半衰期和其他药代动力学性质。